393 related articles for article (PubMed ID: 16283534)
21. Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate.
Coderre TJ; Kumar N; Lefebvre CD; Yu JS
J Neurochem; 2005 Aug; 94(4):1131-9. PubMed ID: 16092950
[TBL] [Abstract][Full Text] [Related]
22. Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.
Schuck E; Bohnert T; Chakravarty A; Damian-Iordache V; Gibson C; Hsu CP; Heimbach T; Krishnatry AS; Liederer BM; Lin J; Maurer T; Mettetal JT; Mudra DR; Nijsen MJ; Raybon J; Schroeder P; Schuck V; Suryawanshi S; Su Y; Trapa P; Tsai A; Vakilynejad M; Wang S; Wong H
AAPS J; 2015 Mar; 17(2):462-73. PubMed ID: 25630504
[TBL] [Abstract][Full Text] [Related]
23. A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling.
Carlsson KC; van de Schootbrugge M; Eriksen HO; Moberg ER; Karlsson MO; Hoem NO
Ther Drug Monit; 2009 Feb; 31(1):86-94. PubMed ID: 19077930
[TBL] [Abstract][Full Text] [Related]
24. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW
Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341
[TBL] [Abstract][Full Text] [Related]
25. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization.
Veyrat-Follet C; Bruno R; Olivares R; Rhodes GR; Chaikin P
Clin Pharmacol Ther; 2000 Dec; 68(6):677-87. PubMed ID: 11180028
[TBL] [Abstract][Full Text] [Related]
26. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model.
Jacqmin P; Snoeck E; van Schaick EA; Gieschke R; Pillai P; Steimer JL; Girard P
J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):57-85. PubMed ID: 17051439
[TBL] [Abstract][Full Text] [Related]
27. Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia.
Parsons B; Tive L; Huang S
Am J Geriatr Pharmacother; 2004 Sep; 2(3):157-62. PubMed ID: 15561647
[TBL] [Abstract][Full Text] [Related]
28. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/2nd communication: promising strategies].
Kuhlmann J
Arzneimittelforschung; 2004; 54(6):307-13. PubMed ID: 15282874
[TBL] [Abstract][Full Text] [Related]
29. A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc.
Rosario MC; Jacqmin P; Dorr P; van der Ryst E; Hitchcock C
Clin Pharmacol Ther; 2005 Nov; 78(5):508-19. PubMed ID: 16321617
[TBL] [Abstract][Full Text] [Related]
30. Starting dose of gabapentin for patients with post-herpetic neuralgia--a dose-response study.
Jean WH; Wu CC; Mok MS; Sun WZ
Acta Anaesthesiol Taiwan; 2005 Jun; 43(2):73-7. PubMed ID: 16060401
[TBL] [Abstract][Full Text] [Related]
31. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
32. Role of modeling and simulation in pediatric investigation plans.
Manolis E; Osman TE; Herold R; Koenig F; Tomasi P; Vamvakas S; Saint Raymond A
Paediatr Anaesth; 2011 Mar; 21(3):214-21. PubMed ID: 21244569
[TBL] [Abstract][Full Text] [Related]
33. Experiences with learning and confirming in drug and biological development.
Patterson SD
Clin Pharmacol Ther; 2010 Aug; 88(2):161-3. PubMed ID: 20648033
[TBL] [Abstract][Full Text] [Related]
34. Decision making from Phase II to Phase III and the probability of success: reassured by "assurance"?
Carroll KJ
J Biopharm Stat; 2013; 23(5):1188-200. PubMed ID: 23957523
[TBL] [Abstract][Full Text] [Related]
35. Integrating dose estimation into a decision-making framework for model-based drug development.
Dunyak J; Mitchell P; Hamrén B; Helmlinger G; Matcham J; Stanski D; Al-Huniti N
Pharm Stat; 2018 Mar; 17(2):155-168. PubMed ID: 29322659
[TBL] [Abstract][Full Text] [Related]
36. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
Taylor DJ; Grobler A; Abdool Karim SS
Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamic effects of a D-amino acid oxidase inhibitor indicate a spinal site of action in rat models of neuropathic pain.
Hopkins SC; Zhao FY; Bowen CA; Fang X; Wei H; Heffernan ML; Spear KL; Spanswick DC; Varney MA; Large TH
J Pharmacol Exp Ther; 2013 Jun; 345(3):502-11. PubMed ID: 23520265
[TBL] [Abstract][Full Text] [Related]
38. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development.
De Ridder F
Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):235-41. PubMed ID: 15733220
[TBL] [Abstract][Full Text] [Related]
39. Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Guay DR
Am J Geriatr Pharmacother; 2005 Dec; 3(4):274-87. PubMed ID: 16503325
[TBL] [Abstract][Full Text] [Related]
40. Pregabalin: new drug. Very similar to gabapentin.
Prescrire Int; 2005 Dec; 14(80):203-6. PubMed ID: 16397976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
